Surrogate approaches in development of monoclonal antibodies.
When cross-reactivity of a lead antibody across species is limited, antibody development programs require the generation of surrogate molecules or surrogate animal models necessary for the conduct of preclinical pharmacology and safety studies. When surrogate approaches are employed, the complexities and challenges for translation of preclinical safety and efficacy results to the clinic are undoubtedly enhanced. Because there are no currently established criteria or regulatory guidance regarding the application of surrogate approaches, a science-based strategy for translation of preclinical information to the clinic is vital for effective development of the lead antibody.
Astrazeneca R&D Boston, PLC, Waltham, MA 02451, USA.
Gadi Gazit
GG
Bornstein
Scott L
SL
Klakamp
Laura
L
Andrews
William J
WJ
Boyle
Mohammad
M
Tabrizi
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D001709:Biotechnology; D003429:Cross Reactions; D016503:Drug Delivery Systems; D015195:Drug Design; D004353:Drug Evaluation, Preclinical / Q000379:methods; D006801:Humans; D007132:Immunoglobulin Isotypes / Q000378:metabolism; D011961:Receptors, Fc / Q000096:biosynthesis / Q000276:immunology; D012107:Research Design; D057170:Translational Research, Biomedical
D000911:Antibodies, Monoclonal; D007132:Immunoglobulin Isotypes; D011961:Receptors, Fc